Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR3591
- Development stage
- Unknown
- Lead developer
- Hengrui Therapeutics
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01
Overview
SHR3591: sourced facts only. name: "We disclose herein SHR3591 as an orally bioavailable AR PROTAC for the treatment of prostate cancer, which is potent in degrading both AR wildtype and LBD mutations." [DOI:10.1158/1538-7445.am2025-396]; target: "We disclose herein SHR3591 as an orally bioavailable AR PROTAC for the treatment of prostate cancer, which is potent in degrading both AR wildtype and LBD mutations." [DOI:10.1158/1538-7445.am2025-396]; developer: "Shanghai Hengrui Pharmaceutical CO., LTD., Shanghai, China." [DOI:10.1158/1538-7445.am2025-396]; modality: "We disclose herein SHR3591 as an orally bioavailable AR PROTAC for the treatment of prostate cancer, which is potent in degrading both AR wildtype and LBD mutations." [DOI:10.1158/1538-7445.am2025-396]
Beyond the preview
Go deeper on SHR3591.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR3591.